﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Society of Diabetic Nephropathy Prevention</PublisherName>
      <JournalTitle>Journal of Nephropharmacology</JournalTitle>
      <Issn>2345-4202</Issn>
      <Volume>8</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2019</Year>
        <Month>01</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>The relationship between dyslipidemia and disease activity in Iranian population with systemic lupus erythematosus</ArticleTitle>
    <FirstPage>e06</FirstPage>
    <LastPage>e06</LastPage>
    <ELocationID EIdType="doi">10.15171/npj.2019.06</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Sepideh</FirstName>
        <LastName>Hajian</LastName>
      </Author>
      <Author>
        <FirstName>Mohammad Ali</FirstName>
        <LastName>Hosseini</LastName>
      </Author>
      <Author>
        <FirstName>Mohadaseh</FirstName>
        <LastName>Ameri</LastName>
      </Author>
      <Author>
        <FirstName>Sara</FirstName>
        <LastName>Khosraviani</LastName>
      </Author>
      <Author>
        <FirstName>Farnaz</FirstName>
        <LastName>Tavasoli</LastName>
      </Author>
      <Author>
        <FirstName>Mohammad Ehsan</FirstName>
        <LastName>Bayatpoor</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.15171/npj.2019.06</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2018</Year>
        <Month>08</Month>
        <Day>06</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2018</Year>
        <Month>10</Month>
        <Day>18</Day>
      </PubDate>
    </History>
    <Abstract>Introduction: In spite of the high prevalence of dyslipidemia in systemic lupus erythematosus (SLE) and its role in patients’ cardiovascular and kidney diseases, few studies had been conducted in this regard. Objectives: We aimed to study the relation between dyslipidemia and disease activity in SLE patients in Iran. Patients and Methods: This analytical cross-sectional study was conducted on SLE patients. The activity of disease was determined by SLE disease activity index (SLEDAI). The serum level of triglyceride (TG), cholesterol, low-density lipoprotein (LDL-C), and high-density lipoprotein (HDL-C) were measured. The correlation between dyslipidemia and SLE disease activity was assessed. Results: Around 62 out of 71 patients (87%) were female (mean age was 34 years). The mean disease duration was 1 year. Around 49% of patients had active disease (SLEDAI ≥6). Proteinuria and nephritis were observed in 18% and 24%, respectively. About 62% of patients had at least one abnormality in their lipid profile. High cholesterol (&gt;200 mg/dL), high TG (&gt;150 md/dL), high LDL-C (&gt;130 mg/dL) and low HDL-C (&lt;50 mg/dL in females and &lt;40 md/dL in males) levels were observed in 25%, 42%, 20% and 49% of patients, respectively. Patients with active disease had lower age and shorter disease duration in comparison to the others (P&lt;0.05). There were no differences in gender and weight between patients in active and inactive phases (P&gt;0.05). Patients with active disease had higher serum cholesterol, TG and LDL-C levels and lower levels of serum HDL-C. Conclusion: It seems that there is a relationship between disease activity and lipid profile abnormalities in SLE patients.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Dyslipidemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Systemic lupus erythematous</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Disease activity</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>